<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312009</url>
  </required_header>
  <id_info>
    <org_study_id>SURG-2020-28675</org_study_id>
    <secondary_id>INV-017069</secondary_id>
    <nct_id>NCT04312009</nct_id>
  </id_info>
  <brief_title>Losartan for Patients With COVID-19 Requiring Hospitalization</brief_title>
  <official_title>Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, double-blinded study of COVID-19 infected patients requiring&#xD;
      inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or&#xD;
      hospital discharge.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 13, 2020</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Estimated (PEEP Adjusted) P/F Ratio at 7 Days</measure>
    <time_frame>7 days</time_frame>
    <description>Outcome calculated from the partial pressure of oxygen or peripheral saturation of oxygen by pulse oximetry divided by the fraction of inspired oxygen (PaO2 or SaO2 : FiO2 ratio). PaO2 is preferentially used if available. A correction is applied for endotracheal intubation and/or positive end-expiratory pressure. Patients discharged prior to day 7 will have a home pulse oximeter send home for measurement of the day 7 value, and will be adjusted for home O2 use, if applicable. Patients who died will be applied a penalty with a P/F ratio of 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily Hypotensive Episodes</measure>
    <time_frame>10 days</time_frame>
    <description>Outcome reported as the mean number of daily hypotensive episodes (MAP &lt; 65 mmHg) prompting intervention (indicated by a fluid bolus &gt;=500 mL) per participant in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Requiring Vasopressors for Hypotension</measure>
    <time_frame>10 days</time_frame>
    <description>Outcome reported as the number of participants in each arm requiring the use of vasopressors for hypotension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Experiencing Acute Kidney Injury</measure>
    <time_frame>10 days</time_frame>
    <description>Outcome reported as the number of participants in each arm who experience acute kidney injury as defined by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines:&#xD;
Increase in serum creatinine by 0.3mg/dL or more within 48 hours OR Increase in serum creatinine to 1.5 times baseline or more within the last 7 days OR Urine output less than 0.5 mL/kg/h for 6 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation / Fractional Inhaled Oxygen (S/F)</measure>
    <time_frame>7 days</time_frame>
    <description>Oxygen saturation (percent) is measured by pulse oximeter. Fraction of inspired oxygen (FiO2) (unitless) is the volumetric fraction of oxygen to other gases in respiratory support. The S/F ratio is unitless.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-Day Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Outcome reported as the number of participants who have expired at 28 days post enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-Day Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Outcome reported as the number of participants who have expired at 90 days post enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Admission</measure>
    <time_frame>10 days</time_frame>
    <description>Outcome reported as the number of participants in each arm who require admission to the Intensive Care Unit (ICU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ventilator-Free Days</measure>
    <time_frame>28 days</time_frame>
    <description>Outcome reported as the mean number of days participants in each arm did not require mechanical ventilation during an in-patient hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Therapeutic Oxygen-Free Days</measure>
    <time_frame>28 days</time_frame>
    <description>Outcome reported as the mean number of days participants in each arm did not require therapeutic oxygen usage during an in-patient hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Vasopressor-Free Days</measure>
    <time_frame>10 days</time_frame>
    <description>Outcome reported as the mean number of days participants in each arm did not require vasopressor usage during an in-patient hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>90 days</time_frame>
    <description>Outcome reported as the mean length of in-patient hospital stay (in days) for participants in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity Rating</measure>
    <time_frame>28 days</time_frame>
    <description>Outcome reported as the number of participants in each arm who fall into each of 7 categories. Lower scores indicate greater condition severity. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Viral Load by Nasopharyngeal Swab Day 15</measure>
    <time_frame>15 days</time_frame>
    <description>Nasopharyngeal swabs will be collected at baseline and day 15. Viral load is measured as number of viral genetic copies per mL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Corona Virus Infection</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive the study drug, Losartan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive a placebo treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan; 50 mg daily; oral administration</description>
    <arm_group_label>Losartan</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presumptive positive laboratory test for Covid-19 based on local laboratory standard&#xD;
&#xD;
          -  Age greater than or equal to 18 years of age&#xD;
&#xD;
          -  Admission to the hospital with a respiratory SOFA &gt;=1 and increased oxygen requirement&#xD;
             compared to baseline among those on home O2&#xD;
&#xD;
          -  Randomization within 48 hours of presentation of hospital admission or within 48 hours&#xD;
             of a positive test result, whichever is later&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Randomization &gt; 48 hours of admission order or positive test result, whichever is&#xD;
             later&#xD;
&#xD;
          -  Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin&#xD;
             receptor blocker (ARB)&#xD;
&#xD;
          -  Prior reaction or intolerance to an ARB or ACE inhibitor, including but not limited to&#xD;
             angioedema&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Lack of negative urine or serum pregnancy test&#xD;
&#xD;
          -  Not currently taking a protocol allowed version of contraception: intrauterine device,&#xD;
             Depo-formulation of hormonal contraception (e.g. medroxyprogesterone acetate /&#xD;
             Depo-Provera), subcutaneous contraceptive (e.g. Nexplanon), daily oral contraceptives&#xD;
             with verbalized commitment to taking daily throughout the study period; use of condoms&#xD;
             or agree to abstain from sexual intercourse during the study. All women of child&#xD;
             bearing age enrolled in this fashion will be informed of the teratogenic risks. If&#xD;
             enrolled under LAR, they will be informed of the risks after regaining capacity.&#xD;
&#xD;
          -  Patient reported history or electronic medical record history of kidney disease,&#xD;
             defined as:&#xD;
&#xD;
               1. Any history of dialysis&#xD;
&#xD;
               2. History of chronic kidney disease stage IV&#xD;
&#xD;
               3. Estimated Glomerular Filtration Rate (eGFR) of &lt; 30ml/min/1.73 m2 at the time of&#xD;
                  randomization&#xD;
&#xD;
          -  Severe dehydration at the time of enrollment in the opinion of the investigator or&#xD;
             bedside clinician&#xD;
&#xD;
          -  Most recent mean arterial blood pressure prior to enrollment &lt;65 mmHg&#xD;
&#xD;
          -  Patient reported history or electronic medical record history of severe liver disease,&#xD;
             defined as:&#xD;
&#xD;
               1. Cirrhosis&#xD;
&#xD;
               2. History of hepatitis B or C&#xD;
&#xD;
               3. Documented AST or ALT &gt; 3 times the upper limit of normal measured within 24&#xD;
                  hours prior to randomization&#xD;
&#xD;
          -  Potassium &gt;5.0 within 24 hours prior to randomization unless a repeat value was &lt;=5.0&#xD;
&#xD;
          -  Treatment with aliskiren&#xD;
&#xD;
          -  Inability to obtain informed consent from participant or legally authorized&#xD;
             representative&#xD;
&#xD;
          -  Enrollment in another blinded randomized clinical trial for COVID&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Tignanelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Puskarich, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Health Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M Health Fairview Ridges Hospital</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M Health Fairview Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M Health Fairview University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Memorial Health Hospital</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2022</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <results_first_submitted>March 15, 2022</results_first_submitted>
  <results_first_submitted_qc>June 27, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2022</results_first_posted>
  <last_update_submitted>June 27, 2022</last_update_submitted>
  <last_update_submitted_qc>June 27, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Corona Virus</keyword>
  <keyword>SARS-COV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04312009/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 2, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04312009/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
        </group>
        <group group_id="P2">
          <title>Losartan</title>
          <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
        </group>
        <group group_id="B2">
          <title>Losartan</title>
          <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="205"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Estimated (PEEP Adjusted) P/F Ratio at 7 Days</title>
        <description>Outcome calculated from the partial pressure of oxygen or peripheral saturation of oxygen by pulse oximetry divided by the fraction of inspired oxygen (PaO2 or SaO2 : FiO2 ratio). PaO2 is preferentially used if available. A correction is applied for endotracheal intubation and/or positive end-expiratory pressure. Patients discharged prior to day 7 will have a home pulse oximeter send home for measurement of the day 7 value, and will be adjusted for home O2 use, if applicable. Patients who died will be applied a penalty with a P/F ratio of 0.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Estimated (PEEP Adjusted) P/F Ratio at 7 Days</title>
          <description>Outcome calculated from the partial pressure of oxygen or peripheral saturation of oxygen by pulse oximetry divided by the fraction of inspired oxygen (PaO2 or SaO2 : FiO2 ratio). PaO2 is preferentially used if available. A correction is applied for endotracheal intubation and/or positive end-expiratory pressure. Patients discharged prior to day 7 will have a home pulse oximeter send home for measurement of the day 7 value, and will be adjusted for home O2 use, if applicable. Patients who died will be applied a penalty with a P/F ratio of 0.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.4" lower_limit="256.7" upper_limit="306.1"/>
                    <measurement group_id="O2" value="260.9" lower_limit="234.1" upper_limit="287.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Hypotensive Episodes</title>
        <description>Outcome reported as the mean number of daily hypotensive episodes (MAP &lt; 65 mmHg) prompting intervention (indicated by a fluid bolus &gt;=500 mL) per participant in each arm.</description>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Hypotensive Episodes</title>
          <description>Outcome reported as the mean number of daily hypotensive episodes (MAP &lt; 65 mmHg) prompting intervention (indicated by a fluid bolus &gt;=500 mL) per participant in each arm.</description>
          <units>episodes per day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048" lower_limit="0.018" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.119" lower_limit="0.065" upper_limit="0.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Requiring Vasopressors for Hypotension</title>
        <description>Outcome reported as the number of participants in each arm requiring the use of vasopressors for hypotension.</description>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Requiring Vasopressors for Hypotension</title>
          <description>Outcome reported as the number of participants in each arm requiring the use of vasopressors for hypotension.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.106"/>
                    <measurement group_id="O2" value="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Experiencing Acute Kidney Injury</title>
        <description>Outcome reported as the number of participants in each arm who experience acute kidney injury as defined by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines:&#xD;
Increase in serum creatinine by 0.3mg/dL or more within 48 hours OR Increase in serum creatinine to 1.5 times baseline or more within the last 7 days OR Urine output less than 0.5 mL/kg/h for 6 hours.</description>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Experiencing Acute Kidney Injury</title>
          <description>Outcome reported as the number of participants in each arm who experience acute kidney injury as defined by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines:&#xD;
Increase in serum creatinine by 0.3mg/dL or more within 48 hours OR Increase in serum creatinine to 1.5 times baseline or more within the last 7 days OR Urine output less than 0.5 mL/kg/h for 6 hours.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.106" lower_limit="0.056" upper_limit="0.174"/>
                    <measurement group_id="O2" value="0.119" lower_limit="0.065" upper_limit="0.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Saturation / Fractional Inhaled Oxygen (S/F)</title>
        <description>Oxygen saturation (percent) is measured by pulse oximeter. Fraction of inspired oxygen (FiO2) (unitless) is the volumetric fraction of oxygen to other gases in respiratory support. The S/F ratio is unitless.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Saturation / Fractional Inhaled Oxygen (S/F)</title>
          <description>Oxygen saturation (percent) is measured by pulse oximeter. Fraction of inspired oxygen (FiO2) (unitless) is the volumetric fraction of oxygen to other gases in respiratory support. The S/F ratio is unitless.</description>
          <units>n/a (ratio)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357.4" lower_limit="330.3" upper_limit="384.5"/>
                    <measurement group_id="O2" value="331.5" lower_limit="302.0" upper_limit="361.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>28-Day Mortality</title>
        <description>Outcome reported as the number of participants who have expired at 28 days post enrollment.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>28-Day Mortality</title>
          <description>Outcome reported as the number of participants who have expired at 28 days post enrollment.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.087" lower_limit="0.031" upper_limit="0.139"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.047" upper_limit="0.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>90-Day Mortality</title>
        <description>Outcome reported as the number of participants who have expired at 90 days post enrollment.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>90-Day Mortality</title>
          <description>Outcome reported as the number of participants who have expired at 90 days post enrollment.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.106" lower_limit="0.045" upper_limit="0.163"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.047" upper_limit="0.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Admission</title>
        <description>Outcome reported as the number of participants in each arm who require admission to the Intensive Care Unit (ICU).</description>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Admission</title>
          <description>Outcome reported as the number of participants in each arm who require admission to the Intensive Care Unit (ICU).</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.272" lower_limit="0.192" upper_limit="0.363"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.270" upper_limit="0.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Ventilator-Free Days</title>
        <description>Outcome reported as the mean number of days participants in each arm did not require mechanical ventilation during an in-patient hospital admission.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Ventilator-Free Days</title>
          <description>Outcome reported as the mean number of days participants in each arm did not require mechanical ventilation during an in-patient hospital admission.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="16.5" upper_limit="20.4"/>
                    <measurement group_id="O2" value="18.1" lower_limit="16.1" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Therapeutic Oxygen-Free Days</title>
        <description>Outcome reported as the mean number of days participants in each arm did not require therapeutic oxygen usage during an in-patient hospital admission.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Therapeutic Oxygen-Free Days</title>
          <description>Outcome reported as the mean number of days participants in each arm did not require therapeutic oxygen usage during an in-patient hospital admission.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" lower_limit="23.1" upper_limit="26.1"/>
                    <measurement group_id="O2" value="23.6" lower_limit="21.8" upper_limit="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Vasopressor-Free Days</title>
        <description>Outcome reported as the mean number of days participants in each arm did not require vasopressor usage during an in-patient hospital admission.</description>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Vasopressor-Free Days</title>
          <description>Outcome reported as the mean number of days participants in each arm did not require vasopressor usage during an in-patient hospital admission.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="9.1" upper_limit="9.8"/>
                    <measurement group_id="O2" value="8.7" lower_limit="8.2" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <description>Outcome reported as the mean length of in-patient hospital stay (in days) for participants in each arm.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <description>Outcome reported as the mean length of in-patient hospital stay (in days) for participants in each arm.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="4.2" upper_limit="7.9"/>
                    <measurement group_id="O2" value="7.1" lower_limit="5.2" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Severity Rating</title>
        <description>Outcome reported as the number of participants in each arm who fall into each of 7 categories. Lower scores indicate greater condition severity. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Severity Rating</title>
          <description>Outcome reported as the number of participants in each arm who fall into each of 7 categories. Lower scores indicate greater condition severity. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="4.0" upper_limit="4.6"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.8" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Viral Load by Nasopharyngeal Swab Day 15</title>
        <description>Nasopharyngeal swabs will be collected at baseline and day 15. Viral load is measured as number of viral genetic copies per mL.</description>
        <time_frame>15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Viral Load by Nasopharyngeal Swab Day 15</title>
          <description>Nasopharyngeal swabs will be collected at baseline and day 15. Viral load is measured as number of viral genetic copies per mL.</description>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" lower_limit="-5.2" upper_limit="-3.1"/>
                    <measurement group_id="O2" value="-4.8" lower_limit="-5.6" upper_limit="-3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 days</time_frame>
      <desc>adverse events were assessed and compared by organ system and not by specific adverse event term</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants in this arm will receive a placebo treatment.&#xD;
Placebo: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration</description>
        </group>
        <group group_id="E2">
          <title>Losartan</title>
          <description>Participants in this arm will receive the study drug, Losartan.&#xD;
Losartan: Losartan; 50 mg daily; oral administration</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematologic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="104"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematologic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="104"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear, Nose, and Throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="104"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="104"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher Tignanelli</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-626-1968</phone>
      <email>ctignane@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

